Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trialResearch in context

Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trialResearch in context

Summary: Background: Allergic rhinitis/rhinoconjunctivitis (AR/C) induced by house dust mites (HDM) often begins in childhood and negatively impacts a child’s quality of life. The daily burden can be further compounded by comorbid asthma. Allergen immunotherapy is the only available treatment targe...

Full description

Saved in:
Bibliographic Details
Main Authors: Antje Schuster, Davide Caimmi, Hendrik Nolte, Silviya Novakova, Jan Mikler, Majken Hougaard Foss-Skiftesvik, Anne Sofie Østerdal, Andrzej Emeryk, Remi Gagnon, Oliver Pfaar
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:The Lancet Regional Health. Europe
Subjects:
Allergic rhinitis
Allergen immunotherapy
House dust mite
Paediatric
SLIT-tablet
Online Access:http://www.sciencedirect.com/science/article/pii/S2666776224003053
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2666776224003053

Similar Items